While no one says ‘cure,’ the pipeline for ALS treatments looks more promising

first_img Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED By Andrew Joseph May 25, 2017 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. APStock Key insight: Several biotech firms, including BrainStorm, AB Science, and Neuraltus, are forging ahead with drugs to treat aspects of ALS. Scientists are hopeful — but cautious.Considering it took more than two decades for a second ALS drug to make it to the US market, you might think that few companies are willing to take the risk of developing such treatments. Biotech Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. While no one says ‘cure,’ the pipeline for ALS treatments looks more promising [email protected] GET STARTEDcenter_img About the Author Reprints General Assignment Reporter Andrew covers a range of topics, from addiction to public health to genetics. Log In | Learn More @DrewQJoseph What’s included? What is it? Andrew Joseph Tags drug developmentneurologySTAT+last_img read more